DRUG QUANTITY MANAGEMENT POLICY – PER DAYS
POLICY: Infectious Disease – Prevymis Drug Quantity Management Policy – Per
Days
• Prevymis™ (letermovir tablets – Merck Sharp & Dohme)
REVIEW DATE: 10/23/2024
INSTRUCTIONS FOR USE
THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA
COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE
DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE
CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS
ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP
SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN
DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR
EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE
POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE
COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY
DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE
REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY
APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE
SPECIFIC FACTS OF THE PARTICULAR SITUATION. EACH COVERAGE REQUEST SHOULD BE REVIEWED ON ITS OWN MERITS. MEDICAL
DIRECTORS ARE EXPECTED TO EXERCISE CLINICAL JUDGMENT AND HAVE DISCRETION IN MAKING INDIVIDUAL COVERAGE
DETERMINATIONS. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES
ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS,
DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.
CIGNA NATIONAL FORMULARY COVERAGE:
OVERVIEW
Prevymis is an antiviral drug indicated for:1
• Cytomegalovirus (CMV) prophylaxis of infection and disease in adult and
pediatric patients ≥ 6 months and weighing ≥ 6 kg who are CMV-seropositive
recipients [R+] of an allogeneic hematopoietic stem cell transplant
(HSCT).
• CMV prophylaxis of disease in adult and pediatric patients ≥ 12 years of
age and weighing ≥ 40 kg who are kidney transplant recipients at high
risk (donor CMV seropositive/recipient CMV seronegative [D+/R-].
Dosing
• Adult and Pediatric Patients ≥ 12 Years of Age and Weighing ≥ 30 kg
Who Are HSCT Recipients or Adult and Pediatric Patients ≥ 12 Years
of Age and Weighing ≥ 40 kg Who Are Kidney Transplant Recipients:
HSCT: The recommended dose is 480 mg once daily (QD) through Day
o
100. In patients at risk for late CMV infection and disease, Prevymis may
be continued through Day 200.
Kidney Transplant: The recommended dose is 480 mg QD through Day
o
200 post-transplant.
Page 1 of 3 - Cigna National Formulary Coverage - Policy: Infectious Disease – Prevymis Drug Quantity
Management Policy – Per Days
• Pediatric Patients 6 Months to < 12 Years of Age or ≥ 12 Years of
Age and Weighing < 30 kg Who Are HSCT Recipients: The dose is
weight based and administered QD through Day 100. In patients at risk for
late CMV infection and disease, Prevymis may be continued through Day 200.
Table 1 below provides the recommend dosing of Prevymis.
Table 1. Recommended Daily Dose in Pediatric HSCT Recipients 6 Months to < 12 Years of
Age and Weighing < 30 kg.
Body Weight (kg) Daily Oral Dose Tablets Oral Pellets
≥ 30 kg 480 mg One 480 mg tablet Four 120 mg packets
15 kg to < 30 kg 240 mg One 240 mg tablet Two 120 mg packets
7.5 kg to < 15 kg 120 mg Not Recommended One 120mg packet
6 kg to < 7.5 kg 80 mg Not Recommended Four 20 mg packets
• The dose of Prevymis should be adjusted based on the patient’s weight when
co-administered with cyclosporine.
Availability
Prevymis tablets are available in the following strengths: 240 mg and 480 mg.1
The tablets are packaged into a carton containing four dose packs, each containing
a 7-count blister card for a total of 28 tablets, or into a carton containing two unit-
dose 7-count blister cards for a total of 14 tablets. Prevymis tablets should be
stored in the original package until use. There are oral pellets approved by the
FDA; however, they are not commercially available and not addressed in this policy.
POLICY STATEMENT
This Drug Quantity Management program has been developed to prevent
stockpiling and waste and to address potential order entry error of Prevymis. If the
Drug Quantity Management rule is not met for the requested medication at the
point of service, coverage will be determined by the Criteria below. All approvals
are provided for 1 year in duration.
Drug Quantity Limits
Product Strength and Form Retail or Home Delivery
Maximum Quantity*
Prevymis™ 240 mg tablets 112 tablets per 365 days
(letermovir tablets) 30 tablets per Rx
480 mg tablets 112 tablets per 365 days
30 tablets per Rx
* Limits may be rounded up to accommodate packaging.
Infectious Disease – Prevymis Drug Quantity Management Policy – Per
Days product(s) is(are) covered as medically necessary when the following
criteria is(are) met. Any other exception is considered not medically
necessary.
3 Pages - Cigna National Formulary Coverage - Policy:Infectious Disease – Prevymis Drug Quantity Management
Policy – Per Days
CRITERIA
1. If the medication is being requested for the prophylaxis of cytomegalovirus in a
high-risk hematopoietic stem cell transplant patient, approve for the requested
quantity, not to exceed a total of 224 tablets per 365 days at retail or home
delivery.
Note: Override quantity is rounded up to accommodate packaging.
2. If the medication is being requested for the prophylaxis of cytomegalovirus in a
high-risk kidney transplant patient, approve for the requested quantity, not to
exceed a total of 224 tablets per 365 days at retail or home delivery.
Note: Override quantity is rounded up to accommodate packaging.
REFERENCES
1. Prevymis® capsules [prescribing information]. Whitehouse Station, NJ: Merck Sharpe & Dohme;
August 2024.
2. Marty FM, Ljungman RF, Cemaly J, et al. Letermovir prophylaxis for cytomegalovirus in
hematopoietic-cell transplantation. N Engl J Med. 2017;377:2433-44.
HISTORY
Type of Summary of Changes Review
Revision Date
Early Annual Override criteria updated to approve the requested quantity, not to 09/27/2023
Revision exceed a total of 224 tablets per 365 days at retail or home delivery
if the medication is being requested for the prophylaxis of
cytomegalovirus in a high-risk kidney transplant patient.
Existing criteria approving the requested quantity if the medication is
being requested for the prophylaxis of cytomegalovirus in a high-risk
hematopoietic stem cell transplant patient was updated to approve
the requested quantity, not to exceed a total of 224 tablets.
Annual No criteria changes. 10/23/2024
Revision
"Cigna Companies" refers to operating subsidiaries of The Cigna Group. All products and services are
provided exclusively by or through such operating subsidiaries, including Cigna Health and Life
Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc.,
Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. ©
2024 The Cigna Group.
3 Pages - Cigna National Formulary Coverage - Policy:Infectious Disease – Prevymis Drug Quantity Management
Policy – Per Days